Quick Answer
Monte Rosa Therapeutics, Inc. reported Cash and Equivalents of $129.88 million for fiscal year 2025.
Monte Rosa Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $129.88M | -42.1% |
| 2024 | $224.25M | +75.1% |
| 2023 | $128.10M | +133.3% |
| 2022 | $54.91M | -84.1% |
| 2021 | $346.07M | +729.9% |
| 2020 | $41.70M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $208.34M | +65.9% | +200.1% |
| June 30, 2025 | $69.43M | -36.2% | -11.6% |
| March 31, 2025 | $78.53M | -21.3% | -65.0% |
| December 31, 2024 | $224.25M | +75.1% | +78.6% |
| September 30, 2024 | $125.58M | +112.6% | +15.4% |
| June 30, 2024 | $108.85M | +131.5% | +9.1% |
| March 31, 2024 | $99.75M | +92.4% | -22.1% |
| December 31, 2023 | $128.10M | +133.3% | +116.9% |
- Monte Rosa Therapeutics, Inc. showed a decrease of -42.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Monte Rosa Therapeutics, Inc.’s cash and equivalents has grown by 211.5% (from $41.70 million to $129.88 million).
- The most recent figure is from Monte Rosa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: